Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/23550
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2021-12-24T08:34:27Z | - |
dc.date.available | 2021-12-24T08:34:27Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | Askari, H. vd. (2009). "Carvedilol therapy in pediatric patients with dilated cardiomyopathy". Turkish Journal of Pediatrics, 51(1), 22-27. | tr_TR |
dc.identifier.issn | 00414301 | - |
dc.identifier.uri | http://hdl.handle.net/11452/23550 | - |
dc.description.abstract | Carvedilol reduces mortality and hospitalization in adults with congestive heart failure. Limited information is available about its use in children. The objective of this study was to determine the dosing, efficacy and side effects of carvedilol for the management of dilated cardiomyopathy in children. Sixteen children with idiopathic dilated cardiomyopathy, aged 7 months to 138 months and with an ejection fraction less than 40%, were treated with carvedilol. The average initial dose was 0.1 mg/kg/day and it was uptitrated to 0.4 mg/kg/day. After six months on carvedilol, there were improvements in clinical scoring system from an average of 2.94 to 2.50 (p<0.05), in mean fractional shortening from 17.2 +/- 6.1% to 22.7 +/- 5.1% (p<0.05), and in ejection fraction from 35.2 6.8% to 43.1 +/- 11.2% (p<0.05). No side effect was observed during the study period. Two patients died due to serious infection. Carvedilol in addition to standard therapy for dilated cardiomyopathy in children improves cardiac function and symptoms. It is well tolerated, with minimal adverse effects, but close monitoring is necessary. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Türk Pediatri Dergisi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Carvedilol | en_US |
dc.subject | Children | en_US |
dc.subject | Dilated cardiomyopathy | en_US |
dc.subject | Congestive-heart-failure | en_US |
dc.subject | Double-blind | en_US |
dc.subject | Children | en_US |
dc.subject | Pediatrics | en_US |
dc.subject.mesh | Adrenergic beta-antagonists | en_US |
dc.subject.mesh | Carbazoles | en_US |
dc.subject.mesh | Cardiomyopathy, dilated | en_US |
dc.subject.mesh | Child | en_US |
dc.subject.mesh | Child, preschool | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Infant | en_US |
dc.subject.mesh | Propanolamines | en_US |
dc.title | Carvedilol therapy in pediatric patients with dilated cardiomyopathy | en_US |
dc.type | Article | tr_TR |
dc.identifier.wos | 000264733700005 | tr_TR |
dc.identifier.scopus | 2-s2.0-65649142978 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı. | tr_TR |
dc.identifier.startpage | 22 | tr_TR |
dc.identifier.endpage | 27 | tr_TR |
dc.identifier.volume | 51 | tr_TR |
dc.identifier.issue | 1 | tr_TR |
dc.relation.journal | Turkish Journal of Pediatrics | en_US |
dc.contributor.buuauthor | Askari, Hülya | - |
dc.contributor.buuauthor | Semizel, Evren | - |
dc.contributor.buuauthor | Bostan, Özlem Mehtap | - |
dc.contributor.buuauthor | Çil, Ergün | - |
dc.contributor.researcherid | AAG-9324-2021 | tr_TR |
dc.contributor.researcherid | AAH-3865-2021 | tr_TR |
dc.indexed.trdizin | TrDizin | tr_TR |
dc.identifier.pubmed | 19378887 | tr_TR |
dc.subject.wos | Pediatrics | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | Pubmed | en_US |
dc.wos.quartile | Q4 | en_US |
dc.contributor.scopusid | 26537185400 | tr_TR |
dc.contributor.scopusid | 12646191300 | tr_TR |
dc.contributor.scopusid | 8676936500 | tr_TR |
dc.contributor.scopusid | 35587943300 | tr_TR |
dc.subject.scopus | Restrictive Cardiomyopathy; Heart Failure; Heart Right Ventricle Dysplasia | en_US |
dc.subject.emtree | Acetylsalicylic acid | en_US |
dc.subject.emtree | Carvedilol | en_US |
dc.subject.emtree | Digoxin | en_US |
dc.subject.emtree | Dipeptidyl carboxypeptidase inhibitor | en_US |
dc.subject.emtree | Furosemide | en_US |
dc.subject.emtree | Beta adrenergic receptor blocking agent | en_US |
dc.subject.emtree | Carbazole derivative | en_US |
dc.subject.emtree | Carvedilol | en_US |
dc.subject.emtree | Propanolamine derivative | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Blood pressure measurement | en_US |
dc.subject.emtree | Child | en_US |
dc.subject.emtree | Clinical article | en_US |
dc.subject.emtree | Congestive cardiomyopathy | en_US |
dc.subject.emtree | Drug dose titration | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug safety | en_US |
dc.subject.emtree | Drug tolerability | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Heart function | en_US |
dc.subject.emtree | Heart left ventricle ejection fraction | en_US |
dc.subject.emtree | Heart rate | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Infant | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Treatment duration | en_US |
dc.subject.emtree | Treatment response | en_US |
dc.subject.emtree | Unspecified side effect | en_US |
dc.subject.emtree | Preschool child | en_US |
Appears in Collections: | Scopus TrDizin Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Askari_vd_2009.pdf | 214.48 kB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License